Associated tags: Pharmacy, FDA, RARE, Science, Medicine, Diabetes, Disease, Incidence, Patient, Mutation, Rare, Pharmaceutical industry
Locations: RARE, UNITED STATES, PENNSYLVANIA
PITTSBURGH, May 1, 2024 /PRNewswire/ -- For a seventh time, PANTHERx Rare has been recognized as the winner of the annual Independent Specialty Pharmacy Patient Choice Award™, with the announcement made at the Asembia Specialty Pharmacy Summit this week.
Key Points:
- PITTSBURGH, May 1, 2024 /PRNewswire/ -- For a seventh time, PANTHERx Rare has been recognized as the winner of the annual Independent Specialty Pharmacy Patient Choice Award™, with the announcement made at the Asembia Specialty Pharmacy Summit this week.
- Since 2016, the Managed Markets Insights & Technology (MMIT) Patient Choice Award has honored the winning specialty pharmacy's exemplary commitment to patients based on the highest average net promoter scores (NPS) from the Zitter Insights Specialty Pharmacy Patient Satisfaction Survey, created to provide independent, objective benchmarking data across U.S. specialty pharmacies.
- "Since day one at PANTHERx I have been personally focused on improving every aspect of the patient experience as the cornerstone of our success," said PANTHERx Rare CEO and Co-founder Rob Snyder.
- We look forward to collaborating with existing and new pharmaceutical partners to bring many more life-saving therapies to market for the people with rare diseases who clearly need them."
FDA,
Bone marrow,
Myelokathexis,
CXCR4,
WHIM syndrome,
Food,
WHIM,
Pharmacy,
Wart,
CXCL12,
Patient,
Hypogammaglobulinemia,
Primary immunodeficiency,
Infection,
Pharmaceutical industry WHIM syndrome is a rare, combined primary immunodeficiency and chronic neutropenic disorder caused by reduced mobilization of white blood cells into the peripheral circulation due to CXCR4/CXCL12 pathway dysfunction.
Key Points:
- WHIM syndrome is a rare, combined primary immunodeficiency and chronic neutropenic disorder caused by reduced mobilization of white blood cells into the peripheral circulation due to CXCR4/CXCL12 pathway dysfunction.
- By targeting the underlying cause of WHIM syndrome, treatment with XOLREMDI results in the increased mobilization of immune cells from the bone marrow.
- "We are very pleased to be working with X4 Pharmaceuticals for the distribution of XOLREMDI in the U.S.," said Rob Snyder, CEO of PANTHERx Rare Pharmacy.
- "Up until now, there has been no treatment specifically indicated in people with WHIM syndrome.
First, the company is expanding geographically beyond its Pittsburgh-region roots to Collierville, TN, near Memphis and FedEx's World Headquarters.
Key Points:
- First, the company is expanding geographically beyond its Pittsburgh-region roots to Collierville, TN, near Memphis and FedEx's World Headquarters.
- This new facility will become the second licensed pharmacy and packaging and dispensing location for PANTHERx Rare®, creating a fully redundant logistics solution.
- This 65,000 sq ft LEED Gold-certified HQ creates a responsible, energizing HQ space to accommodate PANTHERx's future growth and expanding RxARECARE® programs.
- "As the preeminent rare disease pharmacy, our company continues to experience tremendous growth in serving an increasing number of people living with rare conditions who need personalized support," said Rob Snyder, CEO of PANTHERx® Rare Pharmacy.
Disease,
Capsule,
Patient,
Pharmacy,
Bone pain,
Hepatomegaly,
Enzyme replacement therapy,
Anemia,
Gaucher,
Thrombocytopenia,
Liver,
Spleen,
Pharmaceutical industry Yargesa® is a glucosylceramide synthase inhibitor that exerts its effects through a process called substrate reduction therapy.
Key Points:
- Yargesa® is a glucosylceramide synthase inhibitor that exerts its effects through a process called substrate reduction therapy.
- Through this process, Yargesa® reduces the buildup of harmful glycosphingolipids and symptoms of the disease.
- This accumulation leads to manifestations including but not limited to enlarged spleen or liver, hepatomegaly, anemia, thrombocytopenia, and bone pain.
- "We appreciate Edenbridge Pharmaceuticals' commitment to making a difference in the lives of patients with Type 1 Gaucher disease.
Retrieved on:
Wednesday, January 10, 2024
Patient,
Pharmacy,
UCB,
Health care,
REMS,
Neuromuscular junction,
Communication,
FDA,
Diarrhea,
Myasthenia gravis,
Pharmaceutical industry Key Points:
- 1
ZILBRYSQ is available by prescription as a ready-to-use pre-filled syringe that is a once-daily administration.
- Healthcare providers who prescribe ZILBRYSQ must enroll in the ZILBRYSQ REMS because of the serious meningococcal infections.
- The most common side effects of ZILBRYSQ include injection site reactions, upper respiratory tract infections, and diarrhea.
- 1
Myasthenia gravis is a chronic neuromuscular disease that causes weakness in the voluntary muscles.
General Atlantic,
LLP,
Executive,
Change Healthcare,
Health,
Business development,
McKesson Corporation,
Nautic Partners,
Pharmacy,
Growth,
GoodRx,
Organization,
Bansi,
Senior,
Management PITTSBURGH, Jan. 8, 2024 /PRNewswire/ -- PANTHERx Rare, one of the nation's leading rare pharmacies, today announced the appointment of Bansi Nagji to the new board position of Executive Chair as part of the Company's ongoing strategic development and growth.
Key Points:
- PITTSBURGH, Jan. 8, 2024 /PRNewswire/ -- PANTHERx Rare, one of the nation's leading rare pharmacies, today announced the appointment of Bansi Nagji to the new board position of Executive Chair as part of the Company's ongoing strategic development and growth.
- "The Executive Chair role will enhance alignment and engagement between our Board and our Executive Leadership Team to drive successful execution of our key strategic priorities.
- With Bansi's support, we are excited to further our commitment to delivering superior services and driving innovation in all we do," commented Rob Snyder, Chief Executive Officer of PANTHERx Rare.
- PANTHERx Rare is backed by leading investors including Nautic Partners, The Vistria Group, and General Atlantic.
Retrieved on:
Wednesday, August 2, 2023
Extremities,
Neurotransmission,
MuSK protein,
GMG,
Weakness,
Antibody,
Full,
Muscle weakness,
UCB,
Neuromuscular junction,
Patient,
Muscle fatigue,
Acetylcholine receptor,
FDA,
Autoantibody,
Disease,
Pharmaceutical industry Generalized Myasthenia Gravis is a rare, chronic autoimmune disease that results from pathogenic autoantibodies impairing synaptic transmission at the neuromuscular junction.
Key Points:
- Generalized Myasthenia Gravis is a rare, chronic autoimmune disease that results from pathogenic autoantibodies impairing synaptic transmission at the neuromuscular junction.
- 2-3 These autoantibodies primarily consist of AChR or MuSK antibodies.
- 4 The resultant damage manifests as muscle fatigue and weakness.
- We are happy to be able to help some individuals living with Generalized Myasthenia Gravis with the distribution of RYSTIGGO," said Rob Snyder, CEO of PANTHERx® Rare.
Having held several executive positions in prominent organizations is poised to steer PANTHERx Rare toward new heights of success.
Key Points:
- Having held several executive positions in prominent organizations is poised to steer PANTHERx Rare toward new heights of success.
- Ken and Rob's visionary leadership and passion for Rare Pharmacy make them the ideal choice to lead the Company into the future.
- "I am honored to assume the role of President at PANTHERx Rare and work with such a talented team.
- With these leadership changes, PANTHERx Rare is primed for continued success, fortified by exceptional leadership and a team of dedicated professionals.
PITTSBURGH, May 22, 2023 /PRNewswire/ -- For a sixth time, PANTHERx Rare has been recognized as the winner of the annual Independent Specialty Pharmacy Patient Choice Award™.
Key Points:
- PITTSBURGH, May 22, 2023 /PRNewswire/ -- For a sixth time, PANTHERx Rare has been recognized as the winner of the annual Independent Specialty Pharmacy Patient Choice Award™.
- Since 2016, the Managed Markets Insights & Technology (MMIT) Patient Choice Award has honored the winning specialty pharmacy's exemplary commitment to patients based on the highest average net promoter scores (NPS) from the Zitter Insights Specialty Pharmacy Patient Satisfaction Survey, created to provide independent, objective benchmarking data across U.S. specialty pharmacies.
- PANTHERx was founded on the mission to serve people living with rare and devastating conditions.
- "This is the sixth time the MMIT Patient Choice Award has validated our philosophy that in making the best decisions for our patients, we will always make the best decisions for our company," said PANTHERx Rare Chief Executive Officer Rob Snyder.
Triethylenetetramine,
NCC,
Tremor,
Depression,
Psychosis,
Anxiety,
Mutation,
Liver injury,
Jaundice,
Genetic disorder,
Patient,
ATP7B,
Anemia,
Penicillamine,
Liver,
Copper,
Disease PITTSBURGH, April 19, 2023 /PRNewswire/ -- PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to announce the launch of CUVRIOR to treat stable Wilson Disease in adults who are de-coppered and able to take penicillamine.
Key Points:
- PITTSBURGH, April 19, 2023 /PRNewswire/ -- PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to announce the launch of CUVRIOR to treat stable Wilson Disease in adults who are de-coppered and able to take penicillamine.
- Wilson Disease is a rare genetic disorder caused by a mutation in the ATP7B gene, resulting in the accumulation of copper throughout the body.
- CUVRIOR is an innovative oral formulation of the active ingredient trientine created by Orphalan to treat adult patients with stable Wilson Disease who have already been de-coppered.
- In clinical trials, CUVRIOR was found to be well tolerated and non-inferior to penicillamine in reducing non-ceruloplasmin copper (NCC) levels in Wilson Disease patients.
